News | July 29, 2011

InspireMD Launches Randomized Trial for MGuard Mesh Stent

July 29, 2011 — InspireMD Inc., developer of the MGuard mesh protective stent system, announced that the first patient has been enrolled in the MASTER (MGuard for Acute ST Elevation Reperfusion) randomized trial. It is a multinational, randomized, controlled trial designed to demonstrate MGuard coronary stent's superiority over standard care for heart attack patients.

The patient was enrolled in the department of haemodynamics and angiocardiography, headed by Dr. Krystrof Zmudka, at the Krakow Specialist Hospital - John Paul II in Krakow, Poland.

The MASTER trial will enroll 432 patients in a two-arm parallel design. The objective is to demonstrate superiority of the MGuard stent over commercially approved bare-metal stents (BMS) or drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the treatment of acute ST-elevation myocardial infarction (STEMI).

The primary endpoint is complete ST segment resolution. Clinical follow-up will continue for one year. Other important secondary endpoints such as thrombosis in myocardial infarction (TIMI) flow, myocardial blush grade and major adverse cardiac events (MACE) rate will be measured.

Sub studies for cardiac MRI and invasive angiography are planned as well. Gregg Stone, M.D., director of cardiovascular research and education from Columbia University in New York, is the study chairman.

The randomized trial will be carried out in 50 centers throughout Brazil, Canada, Czech Republic, France, Germany, Hungary, Israel, Poland and South Africa. The trial's principal investigators are Alexandre Abizaid, M.D.; Dariusz Dudek, M.D. and Prof. Sigmund Silber.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init